KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Accounts Payables (2016 - 2026)

Bio-Rad Laboratories has reported Accounts Payables over the past 18 years, most recently at $133.1 million for Q1 2026.

  • Quarterly Accounts Payables fell 3.48% to $133.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $133.1 million through Mar 2026, down 3.48% year-over-year, with the annual reading at $129.0 million for FY2025, 5.48% up from the prior year.
  • Accounts Payables was $133.1 million for Q1 2026 at Bio-Rad Laboratories, up from $129.0 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $161.0 million in Q1 2023 and troughed at $102.8 million in Q1 2024.
  • The 5-year median for Accounts Payables is $135.0 million (2022), against an average of $135.6 million.
  • Year-over-year, Accounts Payables tumbled 36.17% in 2024 and then skyrocketed 34.21% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $135.0 million in 2022, then grew by 7.08% to $144.6 million in 2023, then decreased by 15.42% to $122.3 million in 2024, then increased by 5.48% to $129.0 million in 2025, then increased by 3.18% to $133.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Accounts Payables are $133.1 million (Q1 2026), $129.0 million (Q4 2025), and $128.8 million (Q3 2025).